Stocky turns companies like Social Capital Suvretta Holdings Corp. III into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Social Capital Suvretta Holdings Corp. III's latest moves, explained simply — so you know why the numbers change.
Straight from SEC filings · updated 6 Aug 2026Directors guide company strategy; voters chose William Doyle, Alan Lotvin, and Brian Pereira to lead through 2029.
ProKidney expects to complete Phase 3 PROACT 1 enrollment mid-2026 with pivotal results in Q2 2027.
10-Q shows company's assets, liabilities, and operations for the three months ending March 31, 2026.
Annual results show how the company performed financially in 2025 as it develops its kidney treatment.
10-K provides complete picture of company's finances, risks, and operations for the full year 2025.
Updated enrollment goal and timing show the company is advancing kidney disease research toward FDA approval.
Stocky reads Social Capital Suvretta Holdings Corp. III's official filings with the U.S. Securities and Exchange Commission (SEC) — the 8-K, 10-Q and 10-K reports every public company must file — and summarizes each one in plain English, with a link back to the original document.
Social Capital Suvretta Holdings Corp. III's most recent tracked filing was a 8-K on 29 May 2026: Stockholders elect three directors for three-year terms.
No. These event summaries are educational — generated from public SEC filings to help beginners understand what a company is doing. They are not buy or sell recommendations.
This page is just a preview. Open the live, interactive version for the full picture:
Educational, not financial advice. Company events summarized from public SEC filings.
Data as of 6 Aug 2026.